Login to Your Account



Immatics Biotech Raises $52M For Cancer Vaccines

By Cormac Sheridan


Wednesday, February 14, 2007
Billing the investment as the largest venture capital round in German biotechnology since 2001, Immatics Biotechnologies GmbH raised €40 million (US$52.1 million) in a second funding round to further its pipeline of cancer vaccines based on peptides derived from tumor-associated antigens. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription